Lung Tumors and Lung Cancer
Complete English source translationLung Tumors and Lung Cancer
Chengdu Puji Traditional Chinese Medicine Research Institute Chengdu Puji TRADITIONAL CHINESE MEDICINE RESEARCH INSTITUTE Traditional Chinese Medicine Outpatient Department Pui Traditional Chinese Medicine case sharing on tumor rehabilitation patient-…
- Diagnosis
- Lung Tumors and Lung Cancer
- Source materials
- 1 image
- English record
- 794 words
Complete English Translation · Source 1
Chengdu Puji Traditional Chinese Medicine Research Institute
Chengdu Puji TRADITIONAL CHINESE MEDICINE RESEARCH INSTITUTE Traditional Chinese Medicine Outpatient Department
Pui Traditional Chinese Medicine
case sharing on tumor rehabilitation
patient-centered, differentiating treatment based on diagnosis, helping patients live with tumors
patient condition:
Heilongjiang, 65-year-old patient with lung cancer [PATIENT]
examination report shows lung cancer with brain metastasis, surgical resection performed
post-tumor mass, selected traditional Chinese medicine for continuous treatment, initially diagnosed at our hospital in December 2024, reported headache during medication period
Pain and dizziness symptoms have improved; upon follow-up examination in March 2025, significant reduction in intracranial lesions was observed, with lesion extent
significantly reduced.
Verification date N0: 200.12-1
examination region:
9 supply base report (enterprise (m collaboration, examination with medication: 18F-500
tumor
10 doses/1.5 minutes
CT scanning mode and layer thickness: spiral
suitable drug dosage
initial examination report
findings on examination:
mild uptake SUV max: 3.2; left lobe shows unclear appearance, bilateral cerebral hemispheres symmetric, solid tissue radiopharmaceutical distribution
original right side tumor mass resection, partial discontinuity of right superior and lateral bone, slight soft tissue swelling in the area, radiopharmaceutical uptake
fasting state, intravenous injection of 18F-FDG 9.8mCl month
point-like low-density shadows seen in the region, blurred borders, bilateral cerebral sulci and cerebral cisterns widened, all ventricles and cisterns normal in size and shape, midline
generally uniform, left-right symmetric,
seen abnormal radiopharmaceutical uptake increase or low-attenuation foci, poorly uniform solid density, bilateral basal
increased radiopharmaceutical uptake in the region, SUV max: 12.5: oral
evenly distributed, multiple lymph node shadows seen in bilateral neck and cervical regions.
abdominal area shows mild physiological uptake increase, pharynx, larynx
right breast approximately soft tissue mass,
Normal tissue shows mild increased radioactivity uptake,
A brain lesion detected
2.2, pulmonary field shows focal enhancement, bilateral pulmonary texture increased and enhanced, disordered in distribution, a non-regular lesion seen in the lower lobe of left lung near the oblique fissure
Focal nodular tissue density shadow, size approximately: 8*6mm, increased radioactivity uptake SUV max:
Adjacent interlobar pleura shows pleural retraction sign, lesion shows abnormal increased radioactivity uptake SUV max: 7.4: scattered micro-nodules seen in both lungs
Linear tissue-like density shadow, size approximately: 26*9mm, with nodular density increase seen, maximum slice size approximately: 12*8mm,
Abnormal uptake increased SUV max: 8.1: Point-like calcification shadows seen in major vessels and coronary artery course areas, mediastinal pool
High SUV max: 3.2: Bilateral hilar, mediastinal, and right hilar lymph node shadows seen, largest approximately: 425mm radioactivity
Focal, linear, patchy, and reticular density increased shadows, predominantly in the lower lobes of both lungs beneath the pleura, some lesions show increased radioactivity uptake
SUV maximum value in the region of interest (thoracic aortic lcm): 1.8.
Region) SUV max value: 2.8, multiple small cystic low-density shadows seen in the liver, largest with diameter approximately 4mm, no abnormal increased radioactivity uptake detected
Pelvis shows visible bilateral renal and ureteral opacification with diffuse filling defects. Hepatic pool (right hepatic lobe 30mm) shows abnormality
Multiple intestinal tube gas distension shadows observed. Both adrenal glands enlarged, more so on the left, size approximately: 27*17mm, abnormal radioactivity uptake
High. Gastric filling is poor, no obvious FDG metabolic abnormality detected in gastric wall. Intestinal tract shows linear areas of increased radioactivity uptake, intra-abdominal
Increased SUV max: 5.9: Cystic low-density shadow seen, which is isodense
Elective, limb glands, right renal morphology and
Report doctor:
The results of this examination are for reference only by clinical physicians, and should be properly preserved.
Li Shaojie
.0450-[ID REDACTED], [ID REDACTED]
Report date:
2024-12-18
This project is a checking and testing result project in Heilongjiang Province.
Enhanced 1.5T (lung tumor and cranial screening enhanced)
Pathologist 6067
Collection time: 2025-03-27 09:02:55
Examination findings
After 4 months of medication
"Right orbital mass resection post-op" follow-up: after intravenous contrast agent injection, enhanced scan
Description: mild non-uniform enhancement of the right orbital lateral wall and temporal bone. Right frontal lobe, left
in the sella region, patchy and ring-like abnormal enhancing foci are seen, the largest measuring approximately 0.7cm; no abnormal enhancing foci in the rest of the brain parenchyma.
no abnormal enhancing foci in the brain parenchyma; slight enlargement of ventricular system, and slight widening of sulci and gyri.
bed diagnosis
decrease in intracranial lesions
1. Consider 'postoperative changes after right orbital mass resection' based on history; right orbital
heterogeneous enhancement of the lateral wall and temporal bone, 2, multiple intracranial abnormal enhancing foci, combined with history
decreased, lesion range reduced, recommend periodic follow-up.
Consider metastatic tumor; compared to the previous scan in December 2024, the number of lesions has significantly decreased, and the lesion size has shrunk; recommend periodic follow-up.
pharmaceutical 6*
reporting physician 9620
report time 2025-03-27 09:02:55
